The global market for Taditional Chinese Medicine (TCM) for COVID-19 was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Taditional Chinese Medicine (TCM) for COVID-19, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Taditional Chinese Medicine (TCM) for COVID-19 by region & country, by Type, and by Application.

The Taditional Chinese Medicine (TCM) for COVID-19 market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Taditional Chinese Medicine (TCM) for COVID-19.

Market Segmentation

Scope of Taditional Chinese Medicine (TCM) for COVID-19 - Market Report

Report Metric	Details
Report Name	Taditional Chinese Medicine (TCM) for COVID-19 - Market
CAGR	5%
Segment by Type:	Lianhua Qingwen Capsule Jinhua Qinggan Granules Xuebijing Injection TCM Prescription Other
Segment by Application	Hospital Clinic Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Yiling Pharmaceutical, Tianjin Chase Sun Pharmaceutical, Sunflower, Guizhou Yibai Pharmaceutical, Beijing Juxiechang Pharmaceutical, Jiren Pharmaceutical Group, Qingfeng Pharmaceutical Group, Southwest Pharmaceutical, Jiuzhitang, China Beijing Tong Ren Tang Group Co., Ltd., Jiangsu Jichuan Holding Group Co., Ltd.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Taditional Chinese Medicine (TCM) for COVID-19 manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Taditional Chinese Medicine (TCM) for COVID-19 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Taditional Chinese Medicine (TCM) for COVID-19 in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Taditional Chinese Medicine (TCM) for COVID-19 - Market report?

Ans: The main players in the Taditional Chinese Medicine (TCM) for COVID-19 - Market are Yiling Pharmaceutical, Tianjin Chase Sun Pharmaceutical, Sunflower, Guizhou Yibai Pharmaceutical, Beijing Juxiechang Pharmaceutical, Jiren Pharmaceutical Group, Qingfeng Pharmaceutical Group, Southwest Pharmaceutical, Jiuzhitang, China Beijing Tong Ren Tang Group Co., Ltd., Jiangsu Jichuan Holding Group Co., Ltd.

What are the Application segmentation covered in the Taditional Chinese Medicine (TCM) for COVID-19 - Market report?

Ans: The Applications covered in the Taditional Chinese Medicine (TCM) for COVID-19 - Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Taditional Chinese Medicine (TCM) for COVID-19 - Market report?

Ans: The Types covered in the Taditional Chinese Medicine (TCM) for COVID-19 - Market report are Lianhua Qingwen Capsule, Jinhua Qinggan Granules, Xuebijing Injection, TCM Prescription, Other

1 Market Overview

1.1 Taditional Chinese Medicine (TCM) for COVID-19 Product Introduction

1.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Market Size Forecast

1.3 Taditional Chinese Medicine (TCM) for COVID-19 Market Trends & Drivers

1.3.1 Taditional Chinese Medicine (TCM) for COVID-19 Industry Trends

1.3.2 Taditional Chinese Medicine (TCM) for COVID-19 Market Drivers & Opportunity

1.3.3 Taditional Chinese Medicine (TCM) for COVID-19 Market Challenges

1.3.4 Taditional Chinese Medicine (TCM) for COVID-19 Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Players Revenue Ranking (2023)

2.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Revenue by Company (2019-2024)

2.3 Key Companies Taditional Chinese Medicine (TCM) for COVID-19 Manufacturing Base Distribution and Headquarters

2.4 Key Companies Taditional Chinese Medicine (TCM) for COVID-19 Product Offered

2.5 Key Companies Time to Begin Mass Production of Taditional Chinese Medicine (TCM) for COVID-19

2.6 Taditional Chinese Medicine (TCM) for COVID-19 Market Competitive Analysis

2.6.1 Taditional Chinese Medicine (TCM) for COVID-19 Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Taditional Chinese Medicine (TCM) for COVID-19 Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Taditional Chinese Medicine (TCM) for COVID-19 as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Lianhua Qingwen Capsule

3.1.2 Jinhua Qinggan Granules

3.1.3 Xuebijing Injection

3.1.4 TCM Prescription

3.1.5 Other

3.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type

3.2.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, by Type (2019-2030)

3.2.3 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.1.3 Other

4.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application

4.2.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, by Application (2019-2030)

4.2.3 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region

5.1.1 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region (2019-2024)

5.1.3 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region (2025-2030)

5.1.4 Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

5.2.2 North America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

5.3.2 Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

5.4.2 Asia Pacific Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

5.5.2 South America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

5.6.2 Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Taditional Chinese Medicine (TCM) for COVID-19 Sales Value

6.3 United States

6.3.1 United States Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

6.3.2 United States Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

6.4.2 Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

6.5.2 China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

6.5.3 China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

6.6.2 Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

6.7.2 South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

6.8.2 Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019-2030

6.9.2 India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

6.9.3 India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Yiling Pharmaceutical

7.1.1 Yiling Pharmaceutical Profile

7.1.2 Yiling Pharmaceutical Main Business

7.1.3 Yiling Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

7.1.4 Yiling Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) & (2019-2024)

7.1.5 Yiling Pharmaceutical Recent Developments

7.2 Tianjin Chase Sun Pharmaceutical

7.2.1 Tianjin Chase Sun Pharmaceutical Profile

7.2.2 Tianjin Chase Sun Pharmaceutical Main Business

7.2.3 Tianjin Chase Sun Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

7.2.4 Tianjin Chase Sun Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) & (2019-2024)

7.2.5 Tianjin Chase Sun Pharmaceutical Recent Developments

7.3 Sunflower

7.3.1 Sunflower Profile

7.3.2 Sunflower Main Business

7.3.3 Sunflower Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

7.3.4 Sunflower Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) & (2019-2024)

7.3.5 Guizhou Yibai Pharmaceutical Recent Developments

7.4 Guizhou Yibai Pharmaceutical

7.4.1 Guizhou Yibai Pharmaceutical Profile

7.4.2 Guizhou Yibai Pharmaceutical Main Business

7.4.3 Guizhou Yibai Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

7.4.4 Guizhou Yibai Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) & (2019-2024)

7.4.5 Guizhou Yibai Pharmaceutical Recent Developments

7.5 Beijing Juxiechang Pharmaceutical

7.5.1 Beijing Juxiechang Pharmaceutical Profile

7.5.2 Beijing Juxiechang Pharmaceutical Main Business

7.5.3 Beijing Juxiechang Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

7.5.4 Beijing Juxiechang Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) & (2019-2024)

7.5.5 Beijing Juxiechang Pharmaceutical Recent Developments

7.6 Jiren Pharmaceutical Group

7.6.1 Jiren Pharmaceutical Group Profile

7.6.2 Jiren Pharmaceutical Group Main Business

7.6.3 Jiren Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

7.6.4 Jiren Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) & (2019-2024)

7.6.5 Jiren Pharmaceutical Group Recent Developments

7.7 Qingfeng Pharmaceutical Group

7.7.1 Qingfeng Pharmaceutical Group Profile

7.7.2 Qingfeng Pharmaceutical Group Main Business

7.7.3 Qingfeng Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

7.7.4 Qingfeng Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) & (2019-2024)

7.7.5 Qingfeng Pharmaceutical Group Recent Developments

7.8 Southwest Pharmaceutical

7.8.1 Southwest Pharmaceutical Profile

7.8.2 Southwest Pharmaceutical Main Business

7.8.3 Southwest Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

7.8.4 Southwest Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) & (2019-2024)

7.8.5 Southwest Pharmaceutical Recent Developments

7.9 Jiuzhitang

7.9.1 Jiuzhitang Profile

7.9.2 Jiuzhitang Main Business

7.9.3 Jiuzhitang Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

7.9.4 Jiuzhitang Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) & (2019-2024)

7.9.5 Jiuzhitang Recent Developments

7.10 China Beijing Tong Ren Tang Group Co., Ltd.

7.10.1 China Beijing Tong Ren Tang Group Co., Ltd. Profile

7.10.2 China Beijing Tong Ren Tang Group Co., Ltd. Main Business

7.10.3 China Beijing Tong Ren Tang Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

7.10.4 China Beijing Tong Ren Tang Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) & (2019-2024)

7.10.5 China Beijing Tong Ren Tang Group Co., Ltd. Recent Developments

7.11 Jiangsu Jichuan Holding Group Co., Ltd.

7.11.1 Jiangsu Jichuan Holding Group Co., Ltd. Profile

7.11.2 Jiangsu Jichuan Holding Group Co., Ltd. Main Business

7.11.3 Jiangsu Jichuan Holding Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

7.11.4 Jiangsu Jichuan Holding Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Revenue (US$ Million) & (2019-2024)

7.11.5 Jiangsu Jichuan Holding Group Co., Ltd. Recent Developments

8 Industry Chain Analysis

8.1 Taditional Chinese Medicine (TCM) for COVID-19 Industrial Chain

8.2 Taditional Chinese Medicine (TCM) for COVID-19 Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Taditional Chinese Medicine (TCM) for COVID-19 Sales Model

8.5.2 Sales Channel

8.5.3 Taditional Chinese Medicine (TCM) for COVID-19 Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Yiling Pharmaceutical

Tianjin Chase Sun Pharmaceutical

Sunflower

Guizhou Yibai Pharmaceutical

Beijing Juxiechang Pharmaceutical

Jiren Pharmaceutical Group

Qingfeng Pharmaceutical Group

Southwest Pharmaceutical

Jiuzhitang

China Beijing Tong Ren Tang Group Co., Ltd.

Jiangsu Jichuan Holding Group Co., Ltd.

List of Tables

Table 1. Taditional Chinese Medicine (TCM) for COVID-19 Market Trends

Table 2. Taditional Chinese Medicine (TCM) for COVID-19 Market Drivers & Opportunity

Table 3. Taditional Chinese Medicine (TCM) for COVID-19 Market Challenges

Table 4. Taditional Chinese Medicine (TCM) for COVID-19 Market Restraints

Table 5. Global Taditional Chinese Medicine (TCM) for COVID-19 Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Taditional Chinese Medicine (TCM) for COVID-19 Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Taditional Chinese Medicine (TCM) for COVID-19 Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Taditional Chinese Medicine (TCM) for COVID-19 Product Type

Table 9. Key Companies Time to Begin Mass Production of Taditional Chinese Medicine (TCM) for COVID-19

Table 10. Global Taditional Chinese Medicine (TCM) for COVID-19 Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Taditional Chinese Medicine (TCM) for COVID-19 as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region (2019-2024) & (%)

Table 27. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, (2025-2030) & (US$ Million)

Table 31. Yiling Pharmaceutical Basic Information List

Table 32. Yiling Pharmaceutical Description and Business Overview

Table 33. Yiling Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

Table 34. Revenue (US$ Million) in Taditional Chinese Medicine (TCM) for COVID-19 Business of Yiling Pharmaceutical (2019-2024)

Table 35. Yiling Pharmaceutical Recent Developments

Table 36. Tianjin Chase Sun Pharmaceutical Basic Information List

Table 37. Tianjin Chase Sun Pharmaceutical Description and Business Overview

Table 38. Tianjin Chase Sun Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

Table 39. Revenue (US$ Million) in Taditional Chinese Medicine (TCM) for COVID-19 Business of Tianjin Chase Sun Pharmaceutical (2019-2024)

Table 40. Tianjin Chase Sun Pharmaceutical Recent Developments

Table 41. Sunflower Basic Information List

Table 42. Sunflower Description and Business Overview

Table 43. Sunflower Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

Table 44. Revenue (US$ Million) in Taditional Chinese Medicine (TCM) for COVID-19 Business of Sunflower (2019-2024)

Table 45. Sunflower Recent Developments

Table 46. Guizhou Yibai Pharmaceutical Basic Information List

Table 47. Guizhou Yibai Pharmaceutical Description and Business Overview

Table 48. Guizhou Yibai Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

Table 49. Revenue (US$ Million) in Taditional Chinese Medicine (TCM) for COVID-19 Business of Guizhou Yibai Pharmaceutical (2019-2024)

Table 50. Guizhou Yibai Pharmaceutical Recent Developments

Table 51. Beijing Juxiechang Pharmaceutical Basic Information List

Table 52. Beijing Juxiechang Pharmaceutical Description and Business Overview

Table 53. Beijing Juxiechang Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

Table 54. Revenue (US$ Million) in Taditional Chinese Medicine (TCM) for COVID-19 Business of Beijing Juxiechang Pharmaceutical (2019-2024)

Table 55. Beijing Juxiechang Pharmaceutical Recent Developments

Table 56. Jiren Pharmaceutical Group Basic Information List

Table 57. Jiren Pharmaceutical Group Description and Business Overview

Table 58. Jiren Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

Table 59. Revenue (US$ Million) in Taditional Chinese Medicine (TCM) for COVID-19 Business of Jiren Pharmaceutical Group (2019-2024)

Table 60. Jiren Pharmaceutical Group Recent Developments

Table 61. Qingfeng Pharmaceutical Group Basic Information List

Table 62. Qingfeng Pharmaceutical Group Description and Business Overview

Table 63. Qingfeng Pharmaceutical Group Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

Table 64. Revenue (US$ Million) in Taditional Chinese Medicine (TCM) for COVID-19 Business of Qingfeng Pharmaceutical Group (2019-2024)

Table 65. Qingfeng Pharmaceutical Group Recent Developments

Table 66. Southwest Pharmaceutical Basic Information List

Table 67. Southwest Pharmaceutical Description and Business Overview

Table 68. Southwest Pharmaceutical Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

Table 69. Revenue (US$ Million) in Taditional Chinese Medicine (TCM) for COVID-19 Business of Southwest Pharmaceutical (2019-2024)

Table 70. Southwest Pharmaceutical Recent Developments

Table 71. Jiuzhitang Basic Information List

Table 72. Jiuzhitang Description and Business Overview

Table 73. Jiuzhitang Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

Table 74. Revenue (US$ Million) in Taditional Chinese Medicine (TCM) for COVID-19 Business of Jiuzhitang (2019-2024)

Table 75. Jiuzhitang Recent Developments

Table 76. China Beijing Tong Ren Tang Group Co., Ltd. Basic Information List

Table 77. China Beijing Tong Ren Tang Group Co., Ltd. Description and Business Overview

Table 78. China Beijing Tong Ren Tang Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

Table 79. Revenue (US$ Million) in Taditional Chinese Medicine (TCM) for COVID-19 Business of China Beijing Tong Ren Tang Group Co., Ltd. (2019-2024)

Table 80. China Beijing Tong Ren Tang Group Co., Ltd. Recent Developments

Table 81. Jiangsu Jichuan Holding Group Co., Ltd. Basic Information List

Table 82. Jiangsu Jichuan Holding Group Co., Ltd. Description and Business Overview

Table 83. Jiangsu Jichuan Holding Group Co., Ltd. Taditional Chinese Medicine (TCM) for COVID-19 Products, Services and Solutions

Table 84. Revenue (US$ Million) in Taditional Chinese Medicine (TCM) for COVID-19 Business of Jiangsu Jichuan Holding Group Co., Ltd. (2019-2024)

Table 85. Jiangsu Jichuan Holding Group Co., Ltd. Recent Developments

Table 86. Key Raw Materials Lists

Table 87. Raw Materials Key Suppliers Lists

Table 88. Taditional Chinese Medicine (TCM) for COVID-19 Downstream Customers

Table 89. Taditional Chinese Medicine (TCM) for COVID-19 Distributors List

Table 90. Research Programs/Design for This Report

Table 91. Key Data Information from Secondary Sources

Table 92. Key Data Information from Primary Sources

Table 93. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Taditional Chinese Medicine (TCM) for COVID-19 Product Picture

Figure 2. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2019-2030) & (US$ Million)

Figure 4. Taditional Chinese Medicine (TCM) for COVID-19 Report Years Considered

Figure 5. Global Taditional Chinese Medicine (TCM) for COVID-19 Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Taditional Chinese Medicine (TCM) for COVID-19 Revenue in 2023

Figure 7. Taditional Chinese Medicine (TCM) for COVID-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Lianhua Qingwen Capsule Picture

Figure 9. Jinhua Qinggan Granules Picture

Figure 10. Xuebijing Injection Picture

Figure 11. TCM Prescription Picture

Figure 12. Other Picture

Figure 13. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Hospital

Figure 16. Product Picture of Clinic

Figure 17. Product Picture of Other

Figure 18. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 19. Global Taditional Chinese Medicine (TCM) for COVID-19 Sales Value Market Share by Application, 2023 & 2030

Figure 20. North America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2019-2030) & (US$ Million)

Figure 21. North America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (%), 2023 VS 2030

Figure 22. Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2019-2030) & (US$ Million)

Figure 23. Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (%), 2023 VS 2030

Figure 24. Asia Pacific Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2019-2030) & (US$ Million)

Figure 25. Asia Pacific Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (%), 2023 VS 2030

Figure 26. South America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2019-2030) & (US$ Million)

Figure 27. South America Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (%), 2023 VS 2030

Figure 28. Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (2019-2030) & (US$ Million)

Figure 29. Middle East & Africa Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Country (%), 2023 VS 2030

Figure 30. Key Countries/Regions Taditional Chinese Medicine (TCM) for COVID-19 Sales Value (%), (2019-2030)

Figure 31. United States Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, (2019-2030) & (US$ Million)

Figure 32. United States Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

Figure 33. United States Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (%), 2023 VS 2030

Figure 34. Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, (2019-2030) & (US$ Million)

Figure 35. Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

Figure 36. Europe Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (%), 2023 VS 2030

Figure 37. China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, (2019-2030) & (US$ Million)

Figure 38. China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

Figure 39. China Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (%), 2023 VS 2030

Figure 40. Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, (2019-2030) & (US$ Million)

Figure 41. Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

Figure 42. Japan Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (%), 2023 VS 2030

Figure 43. South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, (2019-2030) & (US$ Million)

Figure 44. South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

Figure 45. South Korea Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (%), 2023 VS 2030

Figure 46. Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, (2019-2030) & (US$ Million)

Figure 47. Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

Figure 48. Southeast Asia Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (%), 2023 VS 2030

Figure 49. India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value, (2019-2030) & (US$ Million)

Figure 50. India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Type (%), 2023 VS 2030

Figure 51. India Taditional Chinese Medicine (TCM) for COVID-19 Sales Value by Application (%), 2023 VS 2030

Figure 52. Taditional Chinese Medicine (TCM) for COVID-19 Industrial Chain

Figure 53. Taditional Chinese Medicine (TCM) for COVID-19 Manufacturing Cost Structure

Figure 54. Channels of Distribution (Direct Sales, and Distribution)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global RANKL Inhibitors Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-35Z18485

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Morphine Test Kit - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-28M18423

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Compound Antibacterial Agent for Animal - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-38V14855

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Global Antipyretic Stickers Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-22E8302

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions